Efficacy and Prognostic Factors of Sunitinib as First-Line Therapy for Patients With Metastatic Renal Cell Carcinoma in an Arab Population

PURPOSE: Antiangiogenic tyrosine kinase inhibitors have been the mainstay first-line therapy for metastatic renal cell carcinoma (mRCC). We reviewed the efficacy of first-line therapy with sunitinib in patients with mRCC in an Arab population. METHODS: Medical records of patients with mRCC treated a...

Descripción completa

Detalles Bibliográficos
Autores principales: Badran, Ahmed, Elshenawy, Mahmoud A., Shahin, Amgad, Aljubran, Ali, Alzahrani, Ahmed, Eldali, Abdelmoneim, Bazarbashi, Shouki
Formato: Online Artículo Texto
Lenguaje:English
Publicado: American Society of Clinical Oncology 2020
Materias:
Original Reports
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6998020/
https://www.ncbi.nlm.nih.gov/pubmed/32031432
http://dx.doi.org/10.1200/JGO.19.00111

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6998020/
https://www.ncbi.nlm.nih.gov/pubmed/32031432
http://dx.doi.org/10.1200/JGO.19.00111

Ejemplares similares